Enzo Biochem Inc SEC Filings

Bradley Louis Radoff, a director of Enzo Biochem, Inc. (ENZ), reported on Form 4 that he disposed of a total of 4,533,779 non‑derivative equity interests and an additional 430,000 shares on 08/20/2025, leaving him with 0 shares beneficially owned. The filing explains the dispositions occurred pursuant to the Agreement and Plan of Merger dated June 23, 2025, under which Enzo merged into Bethpage Parent, Inc., and each share of Enzo common stock was canceled and converted into the right to receive $0.70 in cash per share (less withholding). Restricted stock units that vested solely by time for board members were likewise canceled and converted into cash based on the same $0.70 per‑share Merger Consideration. The report is a single‑person Form 4 filed by Radoff and is signed and dated 08/20/2025.

Steven J. Pully, a director of Enzo Biochem, Inc. (ENZ), reported on 08/20/2025 the disposition of 239,992 non-derivative securities in connection with a completed merger.

Per the Merger Agreement, each share of common stock was canceled and converted into the right to receive $0.70 in cash. The reported amount represents 142,897 restricted stock units that vested only by time and 79,365 shares of common stock, which were converted into cash at the merger consideration. Following the transaction the reporting person holds 0 shares.

Patricia Eckert, Chief Financial Officer of Enzo Biochem, Inc. (ENZB), reported transactions on 08/20/2025 related to the company's merger. At the effective time of the Merger, each outstanding share of Enzo common stock was canceled and converted into the right to receive $0.70 in cash per share, less applicable withholding taxes. The filing shows Ms. Eckert disposed of 28,328 shares of common stock and, separately, multiple outstanding stock options (totaling 275,000 options) were cancelled without payment or other consideration under the Merger Agreement. Following these transactions, Ms. Eckert reports owning 0 shares and 0 underlying shares from the cancelled options.

Enzo Biochem insider Jon Couchman reported that all of his holdings in the company were disposed of on 08/20/2025 in connection with a merger that made Enzo a wholly-owned subsidiary. At the Effective Time of the Merger, each share of common stock was cancelled and converted into the right to receive $0.70 in cash per share, net of taxes. The filing shows the cancellation/conversion of 142,897 RSUs and disposals of common stock held directly or indirectly through Xstelos Holdings, Myrexis, the Couchman Family Fund and his retirement accounts, leaving 0 shares beneficially owned following the transactions.

Enzo Biochem insider filings show the company's merger closed and equity holdings were converted or canceled. The reporting person, Kara Cannon, who served as Chief Executive Officer and director, disposed of 359,737 shares of common stock and 45,065 shares held indirectly in a 401(k) on 08/20/2025. Under the Merger Agreement dated June 23, 2025, each share of common stock was canceled and converted into the right to receive $0.70 in cash per share. Time-vested RSUs held by directors were similarly converted into cash based on underlying shares. Outstanding stock options were canceled at the Effective Time without any cash payment or other consideration.